Cognition Therapeutics, Inc. announced that its Phase 2 ‘START’ study of Zervimesine (CT1812) in individuals with mild cognitive impairment or early Alzheimer’s disease has reached 75 % of its targeted enrollment of approximately 540 participants, according to the company.
The START study, supported by an $81 million grant from the National Institute on Aging at the National Institutes of Health, is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium and spans 35 academic sites. Participants will be randomized to receive once-daily oral Zervimesine or placebo for 18 months.
Cognition Therapeutics said that this marks the largest Phase 2 trial it has conducted to date, and the second targeting Alzheimer’s disease. In 2024, the company reported results from its SHINE study in mild-to-moderate Alzheimer’s patients, which it said showed Zervimesine slowed cognitive decline in individuals with lower p-tau217 levels. The START study aims to evaluate the drug’s efficacy in earlier stages of disease progression.
Zervimesine is an investigational, once-daily oral therapy under development for central nervous system disorders including Alzheimer’s disease and dementia with Lewy bodies.
